Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Delphine Guyon-Gellin, n/a
Chief Business Development Officer
Osivax, French Guiana
Poster(s):
(372) Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical trial
Thursday, October 12, 2023
12:15 PM – 1:30 PM
US ET
